Summary by Moomoo AI
CRISPR Therapeutics, a leading gene editing company, has reported significant financial and business developments in its latest quarterly report. Financially, the company has issued 1.5 million common shares under the 2021 ATM at an average price of $139.28 per share, resulting in aggregate proceeds of $212.4 million net of equity issuance costs. Additionally, CRISPR Therapeutics entered into a registered direct offering in February 2024, selling approximately $280.0 million of its common shares at $71.50 per share, with net proceeds of $279.0 million. The company did not generate material revenue for the quarter ended March 31, 2024, compared to $100.0 million in the same period the previous year, primarily from an upfront payment from Vertex. Research and development expenses decreased to $76.2 million from $99.9 million year-on-year, while general and administrative expenses...Show More